Kymera Therapeutics, Inc.
(NASDAQ : KYMR)

( )
KYMR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.01%170.190.7%$968.89m
PFEPfizer Inc. 0.42%49.780.9%$831.56m
ABBVAbbVie, Inc. -0.06%140.261.9%$828.10m
MRKMerck & Co., Inc. 1.18%89.530.7%$782.75m
LLYEli Lilly & Co. 0.15%302.941.1%$765.74m
BMYBristol-Myers Squibb Co. 1.59%74.971.0%$667.48m
SIGASIGA Technologies, Inc. 2.70%22.790.0%$421.60m
AZNAstraZeneca Plc 1.18%65.891.0%$366.83m
ALNYAlnylam Pharmaceuticals, Inc. -3.19%223.378.1%$270.23m
GBTGlobal Blood Therapeutics, Inc. -0.02%66.595.6%$260.89m
GSKGSK Plc -0.79%39.990.3%$212.92m
HZNPHorizon Therapeutics Plc -3.63%67.125.4%$204.87m
NVSNovartis AG 1.39%87.130.2%$176.66m
CCXIChemoCentryx, Inc. -0.20%50.792.9%$168.36m
SGENSeagen Inc. -1.53%175.605.7%$163.66m

Company Profile

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.